Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis
Purpose. To evaluate the intense pulsed light (IPL) therapy with optimal pulse technology (OPT, M22™, Lumenis, USA) as an adjunct therapy for the prevention of recurrences in moderate to severe blepharokeratoconjunctivitis (BKC). Methods. This open-label nonrandomized clinical trial evaluated 33 pat...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2019/3143469 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551521417428992 |
|---|---|
| author | Fang Ruan Yunxiao Zang Ruti Sella Hongshuang Lu Shang Li Ke Yang Tao Jin Natalie A. Afshari Zhiqiang Pan Ying Jie |
| author_facet | Fang Ruan Yunxiao Zang Ruti Sella Hongshuang Lu Shang Li Ke Yang Tao Jin Natalie A. Afshari Zhiqiang Pan Ying Jie |
| author_sort | Fang Ruan |
| collection | DOAJ |
| description | Purpose. To evaluate the intense pulsed light (IPL) therapy with optimal pulse technology (OPT, M22™, Lumenis, USA) as an adjunct therapy for the prevention of recurrences in moderate to severe blepharokeratoconjunctivitis (BKC). Methods. This open-label nonrandomized clinical trial evaluated 33 patients diagnosed with BKC. Twenty-one patients received four bilateral OPT therapy sessions with Meibomian gland expression (MGX) (treatment group), and 11 patients received MGX alone (controls). This trial was initiated after a four-week pharmacotherapy for BKC in both groups and was scheduled at four-week intervals. Efficacy outcome measures included meibum quality, Meibomian gland (MG) secretion function, eyelid margin signs, corneal fluorescein staining (CFS) score, noninvasive keratography breakup time (NIKBUT), ocular surface disease index (OSDI) score, Schirmer I test (SIT), classification of tear film lipid layer (TFLL), and Meibomian gland dropout (MGDR). Safety outcome measures included visual acuity, intraocular pressure, eye structure damage, and facial skin appearance at each visit. Results. Quality of meibum, MG expressibility, eyelid margin signs, and OSDI score showed a statistically significant greater improvement in the treatment group after one to three treatment sessions, compared to controls (p<0.05). While these improved in both groups in comparison to baseline, the NIKBUT and upper and lower eyelid MGDRs significantly improved only in the treatment group (p<0.05). No adverse events occurred in both groups. No BKC recurrences were noted in the treatment group. Conclusions. IPL is a safe and effective adjuvant treatment for BKC and possibly more effective in reducing eyelid margin inflammation and prevents recurrences than MGX alone. This trial is registered with ChiCTR-ONN-17013864. |
| format | Article |
| id | doaj-art-305b5065e5fc4a8896c75e7fa3e6fff4 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-305b5065e5fc4a8896c75e7fa3e6fff42025-02-03T06:01:15ZengWileyJournal of Ophthalmology2090-004X2090-00582019-01-01201910.1155/2019/31434693143469Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated KeratoconjunctivitisFang Ruan0Yunxiao Zang1Ruti Sella2Hongshuang Lu3Shang Li4Ke Yang5Tao Jin6Natalie A. Afshari7Zhiqiang Pan8Ying Jie9Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, ChinaShiley Eye Institute, Department of Ophthalmology, University of California San Diego, La Jolla, San Diego, CA, USABeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, ChinaShiley Eye Institute, Department of Ophthalmology, University of California San Diego, La Jolla, San Diego, CA, USABeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, ChinaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, ChinaPurpose. To evaluate the intense pulsed light (IPL) therapy with optimal pulse technology (OPT, M22™, Lumenis, USA) as an adjunct therapy for the prevention of recurrences in moderate to severe blepharokeratoconjunctivitis (BKC). Methods. This open-label nonrandomized clinical trial evaluated 33 patients diagnosed with BKC. Twenty-one patients received four bilateral OPT therapy sessions with Meibomian gland expression (MGX) (treatment group), and 11 patients received MGX alone (controls). This trial was initiated after a four-week pharmacotherapy for BKC in both groups and was scheduled at four-week intervals. Efficacy outcome measures included meibum quality, Meibomian gland (MG) secretion function, eyelid margin signs, corneal fluorescein staining (CFS) score, noninvasive keratography breakup time (NIKBUT), ocular surface disease index (OSDI) score, Schirmer I test (SIT), classification of tear film lipid layer (TFLL), and Meibomian gland dropout (MGDR). Safety outcome measures included visual acuity, intraocular pressure, eye structure damage, and facial skin appearance at each visit. Results. Quality of meibum, MG expressibility, eyelid margin signs, and OSDI score showed a statistically significant greater improvement in the treatment group after one to three treatment sessions, compared to controls (p<0.05). While these improved in both groups in comparison to baseline, the NIKBUT and upper and lower eyelid MGDRs significantly improved only in the treatment group (p<0.05). No adverse events occurred in both groups. No BKC recurrences were noted in the treatment group. Conclusions. IPL is a safe and effective adjuvant treatment for BKC and possibly more effective in reducing eyelid margin inflammation and prevents recurrences than MGX alone. This trial is registered with ChiCTR-ONN-17013864.http://dx.doi.org/10.1155/2019/3143469 |
| spellingShingle | Fang Ruan Yunxiao Zang Ruti Sella Hongshuang Lu Shang Li Ke Yang Tao Jin Natalie A. Afshari Zhiqiang Pan Ying Jie Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis Journal of Ophthalmology |
| title | Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis |
| title_full | Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis |
| title_fullStr | Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis |
| title_full_unstemmed | Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis |
| title_short | Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis |
| title_sort | intense pulsed light therapy with optimal pulse technology as an adjunct therapy for moderate to severe blepharitis associated keratoconjunctivitis |
| url | http://dx.doi.org/10.1155/2019/3143469 |
| work_keys_str_mv | AT fangruan intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT yunxiaozang intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT rutisella intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT hongshuanglu intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT shangli intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT keyang intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT taojin intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT natalieaafshari intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT zhiqiangpan intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis AT yingjie intensepulsedlighttherapywithoptimalpulsetechnologyasanadjuncttherapyformoderatetosevereblepharitisassociatedkeratoconjunctivitis |